Compugen Ltd (CGEN)

[J.D. Penny]

Fair assessment but the pipeline is as strong as ever and a lot of big pharma cant even come close to the propspects Compugen has. Nov 11 stands out as another big date for investors. Lets see how earnings or any other announcements prior to 2020 pan out.

$6.50 plus before end of the year.

[CarlsJ]

Fun's over. This might be -30% tomorrow. The announcements about COM2 and COM1 really weren't very important, and there are no more catalysts in the foreseeable future. It's back to just burning cash with no end in sight since everything they have is super early.

[J.D. Penny]

Nailed it!! Over $6 today. Boom.

[J.D. Penny]

Compugen Presents Initial Clinical Data from Ongoing Phase 1 Trial of
COM701 in Patients with Advanced Solid Tumors at SITC 2019

"We look forward to initiating our biomarker driven COM701 monotherapy expansion cohorts in these four prioritized indications -- ovarian, endometrial, breast and lung cancers."

https://www.cgen.com/wp-content/uploads/COM701-SITC-data-Final-05-11-2019.pdf

[J.D. Penny]

Pre-market trading shows a $5.50 plus open. I’ve been in and out of this stock since 2003. It’s been a sleeping giant all along. Here we go.

[J.D. Penny]

CGEN DAILY CHART 11.4.19

[J.D. Penny]

CGEN is a rocket ship going past the moon! End of 2019 is going to be epic.

[jonny_red]

3 Penny Stocks Ripping Higher In October --->

$BGFV $SSKN $CGEN

#stockstowatch #trader #stockmarket #pennystocks #business #investor #marketing

https://www.transparenttraders.me/2019/10/3-penny-stocks-ripping-higher-in.html

[whytestocks]

News: $CGEN Compugen Announces Purchase of Company Shares by its Board of Directors and Members of Management

HOLON, Israel , March 26, 2019 /PRNewswire/ --  Compugen Ltd.  (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced that its entire board of directors and members of management purchased Company shares on the op...

Read the whole news https://marketwirenews.com/news-releases/compugen-announces-purchase-of-company-shares-by-its-board-of-directors-and-members-of-management-7889734.html

[whytestocks]

News: $CGEN Compugen Announces Publication of Two Peer-Reviewed Papers Demonstrating the Role of PVRIG as a Novel Immune Checkpoint for Cancer Immunotherapy

HOLON, Israel , Jan. 22, 2019 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, today announced the online publication of preclinical data demonstrating the role of PVRIG as a novel immune checkpoint an...

In case you are interested https://marketwirenews.com/news-releases/compugen-announces-publication-of-two-peer-reviewed-papers-demonstrating-the-role-of-pvrig-as-a-novel-immune-checkpoint-for-cancer-immunotherapy-7412678.html

[Golden Cross]

CGEN cheat sheet

https://www.barchart.com/stocks/quotes/CGEN/cheat-sheet

[Golden Cross]

50dma/200dma converging towards a cross... very bullish imo

[Golden Cross]

Money flow very strong

[Golden Cross]

Compugen to Present at the Cowen and Company 38th Annual Health Care Conference
Date : 03/08/2018 @ 7:00AM
Source : PR Newswire (US)
Stock : Compugen Ltd. - Ordinary Shares (CGEN)
Quote : 4.1 0.0 (0.00%) @ 8:00PM

Compugen to Present at the Cowen and Company 38th Annual Health Care Conference
Print
Alert
Compugen Ltd. - Ordinary Shares (NASDAQ:CGEN)
Historical Stock Chart
1 Month : From Feb 2018 to Mar 2018

Click Here for more Compugen Ltd. - Ordinary Shares Charts.
HOLON, Israel, March 8, 2018 /PRNewswire/ --

Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that Anat Cohen-Dayag, PhD, President and CEO of Compugen, will present a corporate overview and update at the Cowen and Company 38th Annual Health Care Conference in Boston, on Tuesday, March 13, 2018, at 10:40 AM.

A live webcast of the presentation will be available on Compugen's website. A replay will be available after the presentation ends.

Also at the Cowen Health Care Conference, on March 14, 2018, at 12:45 PM, Charles Drake, MD, PhD, Director, Genitourinary Oncology, Co-Director Immunotherapy Program, Associate Director, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center and a member of Compugen's scientific advisory board, will take part in a panel titled 'Novel Immuno-Oncology Drug Candidates'.

About Compugen

Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at http://www.cgen.com.

Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: [e-mail]
Tel: [phone]

Investor Relations contact:
Burns McClellan, Inc.
Jill Steier
Email: [e-mail]
Tel: [phone]
SOURCE Compugen Ltd.


Copyright 2018 PR Newswire

[Golden Cross]

Compugen Reports Fourth Quarter and Full Year 2017 Results
Date : 02/21/2018 @ 7:07AM
Source : PR Newswire (US)
Stock : Compugen Ltd. - Ordinary Shares (CGEN)
Quote : 4.1 0.0 (0.00%) @ 8:00PM

Compugen Reports Fourth Quarter and Full Year 2017 Results
Print
Alert
Compugen Ltd. - Ordinary Shares (NASDAQ:CGEN)
Historical Stock Chart
1 Month : From Feb 2018 to Mar 2018

Click Here for more Compugen Ltd. - Ordinary Shares Charts.
HOLON, Israel, Feb. 21, 2018 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financial results for the fourth quarter and full year ended December 31, 2017.

"2017 was a significant year for Compugen, in which we made important progress in advancing our therapeutic pipeline and strengthening core competencies in target discovery and validation, and therapeutic antibody development. Today there are four preclinical stage programs in our pipeline, originating from our discovery capabilities, as well as a portfolio of earlier stage programs focused on myeloid targets, a newly-rising and promising field in cancer immunotherapy. We also broadened our R&D infrastructure with a research collaboration agreement with The Mount Sinai Hospital, in addition to the collaboration we already have with John Hopkins University School of Medicine," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen.

"We are finalizing our clinical protocol and IND application for COM701, our first-in-class therapeutic antibody candidate targeting PVRIG, and are on track to file the IND with the FDA, as planned, towards the end of the first quarter of 2018. Our Phase 1 clinical trial is expected to start later in 2018."

"Bayer is also continuing to advance the CGEN-15001T program, a novel immune checkpoint inhibitor targeting ILDR2, through late preclinical development for cancer immunotherapy, and plans to present, for the first time, data supportive of the potential of ILDR2 to serve as a promising target for cancer immunotherapy at an upcoming scientific meeting. This further demonstrates the value and success of Compugen's computational discovery capabilities and its high-quality outputs."

"With two product-candidates against Compugen-discovered novel targets in late stage preclinical development, we are well positioned to continue executing our plan of developing first-in-class therapeutics targeted at novel pathways with the potential of generating new treatment solutions for patients unresponsive and refractory to existing immunotherapies," concluded Dr. Cohen-Dayag.

Paul Sekhri, Chairman of the Board of Directors of Compugen, added, "This is an exciting time for Compugen as we become a clinical stage company. Compugen's uniqueness lies in its unparalleled computational discovery capabilities, coupled with expert immuno-oncology and antibody development groups and led by a strong management team, allowing for the generation of first-in-class drug opportunities and commercially valuable assets. With the recent advancements in our pipeline, I believe Compugen holds significant clinical and commercial value which will drive our future growth."

Recent highlights:

Announced publication of two peer-reviewed papers in The Journal of Immunology on the discovery and validation of the ILDR2 protein as a novel immune checkpoint and its use as an Fc fusion protein for the treatment of autoimmune diseases.
Presented new preclinical data on COM701 demonstrating distinctive features of the PVRIG pathway and the potential of COM701 for treating multiple solid tumors. The data presented also support the Company's biomarker strategy and clinical development program for COM701, as a monotherapy and in combination treatment with COM902, Compugen's therapeutic antibody candidate targeting TIGIT, and with PD-1 blockers.
Financial Results

R&D expenses for the fourth quarter and year ended December 31, 2017 were $7.2 million and $28.6 million, respectively, compared with $6.3 million and $24.5 million for the comparable periods in 2016. The increase continues to reflect the expanded preclinical development activities involving our pipeline program candidates, mainly related to COM701 as well as COM902.

Net loss for the fourth quarter of 2017 was $9.3 million, or $0.18 per diluted share, compared with a net loss of $8.5 million, or $0.17 per diluted share, in the comparable periods of 2016. Net loss for the year ended December 31, 2017 was $37.1 million, or $0.72 per diluted share, compared with a net loss of $31.5 million, or $0.62 per diluted share, for the year ended December 31, 2016.

As of December 31, 2017, cash, cash related accounts, short-term and long-term bank deposits totaled $30.4 million, compared with $61.5 million at December 31, 2016. The Company has no debt.

Conference Call and Webcast Information

Compugen will hold a conference call to discuss its fourth quarter and full year 2017 results today, February 21, 2018, at 10:00 a.m. ET. To access the live conference call by telephone, please dial [phone] from the U.S., or [phone] internationally. The conference call will also be available via live webcast through Compugen's website, located at the following link. Following the live audio webcast, a replay will be available on the Company's website.

(Tables to follow)

About Compugen

Compugen is a therapeutic discovery and development company utilizing its broadly applicable predictive discovery infrastructure to identify novel drug targets and develop first-in-class therapeutics in the field of cancer immunotherapy. The Company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets it has discovered, including T cell immune checkpoints and myeloid target programs. Compugen's business model is to selectively enter into collaborations for its novel targets and related drug product candidates at various stages of research and development. The Company is headquartered in Israel, with R&D facilities in both Israel and South San Francisco, CA. Compugen's shares are listed on NASDAQ and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

For additional information, please visit Compugen's corporate website at: www.cgen.com.

Forward-Looking Statement

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as "will," "may," "expects," "anticipates," "believes," "potential," "plan," "goal," "estimate," "likely," "should," "confident," and "intends," and describe opinions about possible future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties, Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model. Moreover, the development and commercialization of therapeutic candidates involve many inherent risks, including failure or delay to progress to clinical trials or, if they progress to or enter clinical trials, failure to receive regulatory approval. These and other factors, including the ability to finance the Company, are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

[krk]

CGEN dropped from the Nasdaq Biotech Index on 11-Dec @2.50 and has kept going up since with a big price and volume spike on 15-Dec.
Doesn't make sense !!

[shub]

I sold a bit on that peak at $4, and now it's settled back down so i put in a limit order to buy it back at $3.
Our big advantage in being able to identify onco-checkpoints first, is largely gone as the technology advances. But i presume that we've made significant advances ourselves and have been developing our discoverys for some time, giving us the first comer's advantage.
Initially i'd anticipated big pharma lining up outside our doors, clamoring for leads, given their own inability to produce original discoveries...But no pie. So we're going forward ourselves.

[shub]

Up 17% . Just nailed the patent on our lead immune-onco drug.
"COM701 is a humanized hybridoma antibody that binds with high affinity to PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen, blocking its interaction with PVRL2. Blockade of PVRIG by COM701 has demonstrated potent, reproducible enhancement of T cell activation, consistent with the desired mechanism of action of activating T cells in the tumor microenvironment to generate anti-tumor immune responses. In addition, COM701 combined with antagonist anti-TIGIT or anti-PD1 antibodies has demonstrated synergistic effect on human T cell stimulation, indicating the potential of these combinations to further enhance immune response against tumors."
And we've got at least a dozen more in the works.

[shub]

We have some but obviously need more.
Even a small pharm would do if they'd take a candidate and run with it.
I just don't understand why these checkpoint candidates aren't being gobbled up by an industry obviously short of productive and original ideas....
.Well, except for the staggering cost of getting a new drug through the FA.

[shub]

At the risk of being redundant...Check this out!

Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, disclosed today new animal model results demonstrating restoration of immune tolerance by CGEN-15001, the Company's lead candidate for treatment of autoimmune diseases. Importantly, the immune tolerance established by CGEN-15001 was shown to be antigen-specific, indicating that treatment with CGEN-15001 has the potential to not only generate a durable response, but also to avoid the global immune suppression generated by other therapeutic agents for autoimmune diseases. CGEN-15001 is an Fc fusion protein based on a Compugen-discovered novel immune checkpoint protein.

That means we can treat and protect specific autoimmune disease targets...some of the most common and intractable curses of mankind!

If this proves out, we should come out of this with bulging pockets and feeling a whole lot better besides!

[shub]

hey, that new 15001 candidate looks incredibly promising!
It's just in mice thus far, so the odds are a bit long, but if it works in people, we'd be on top of the immunological world!

[redspinelpinktopaz]

Blue fin: Are we waiting for a big pharma 15001 partner to be announced?

[Blue Fin]

New power point presentation and press release:

http://www.cgen.com/data/upl/Presentations/Corporate%20presentation%20Piper%20Jaffray%20November%202016.pdf

http://www.cgen.com/data/upl/PressReleases/2016.11.11%20SITC%202016%20Presentation%20announcement.pdf

[Blue Fin]

http://www.businesswire.com/news/home/20161115006621/en/Piper-Jaffray-Host-28th-Annual-Healthcare-Conference

Piper Jaffray to Host 28th Annual Healthcare Conference
November 15, 2016 02:25 PM Eastern Standard Time
NEW YORK--(BUSINESS WIRE)--Piper Jaffray Companies (NYSE: PJC), a leading investment bank and asset management firm, will host its 28th annual Healthcare Conference in New York on November 29-30, 2016.

[Blue Fin]

Some more expectations for R&D day.


http://www.streetinsider.com/Analyst+Comments/Compugens+(CGEN)+COM701+Could+Make+R%26D+Day+A+Catalyst+-+FBR/12289666.html

Compugen's (CGEN) COM701 Could Make R&D Day A Catalyst - FBR
November 29, 2016 6:50 AM EST
FBR Capital analyst, Vernon Bernadino, reiterated his Outperform rating on shares of Compugen (NASDAQ: CGEN) as COM701 emerges shifts from ....

[shub]

My guess is that the PPS will keep yo-yoing around until we see some of our findings turned into successful drugs...Or at least start selling some of them for a fair price.
The longer we don't, the greater BP's in silica capabilities will grow.

[Alpine600]

Stock price warmed up nicely on Friday and given 3x normal volume I wonder if we hit new 52 week high shortly

[shub]

The hot, multibillion dollar drugs in immune oncology now are PD-1 inhibitors.
CGEN has a fat double handful more checkpoint inhibitors ready for testing with more coming.
I don't understand why BP isn't swarming all over them waving fat multi million dollar deals at us?

[stocktrademan]

CGEN bullish 6.99

nasdaq stocks $1-10 with volume > 100,000

[stocktrademan]

$CGEN recent news/filings

bullish 7.54
resistance breakout
uptrending higher highs higher lows

## source: finance.yahoo.com

Wed, 25 Nov 2015 23:28:49 GMT ~ Seneca Foods Corp (SENEA): Are Hedge Funds Right About This Stock?


read full: http://www.insidermonkey.com/blog/seneca-foods-corp-senea-are-hedge-funds-right-about-this-stock-389296/
*********************************************************

Tue, 24 Nov 2015 13:13:38 GMT ~ Compugen to Present at the Oppenheimer Healthcare Conference in New York

[at noodls] - 263e58e9-e35a-4356-879d-b0c60673032c.pdf FOR IMMEDIATE RELEASE Tel Aviv, Israel - November 24, 2015 - Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Ari ...

read full: http://www.noodls.com/view/7B34337F6D7EA3237CEF57A94685982ED7E6C8C6
*********************************************************

Tue, 24 Nov 2015 12:00:00 GMT ~ Compugen to Present at the Oppenheimer Healthcare Conference in New York

[Business Wire] - Compugen Ltd. , a leading predictive drug discovery company, today announced that Ari Krashin, Chief Financial Officer of Compugen, will present a corporate overview and update at the Oppenheimer 26th Annual Healthcare Conference in New York, on Tuesday, December 8, 2015.

read full: http://finance.yahoo.com/news/compugen-present-oppenheimer-healthcare-conference-120000947.html
*********************************************************

Thu, 12 Nov 2015 13:16:03 GMT ~ Compugen to Present at Jefferies 2015 Global Healthcare Conference in London

[at noodls] - 90f60e8b-731a-4e9b-86f8-2872812c6014.pdf FOR IMMEDIATE RELEASE Tel Aviv, Israel - November 12, 2015 - Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today announced that Dr. ...

read full: http://www.noodls.com/view/6A77E2809F38C15DC5F1A3886329C7713FAA308D
*********************************************************

Thu, 12 Nov 2015 12:00:00 GMT ~ Compugen to Present at Jefferies 2015 Global Healthcare Conference in London


read full: http://uk.finance.yahoo.com/news/compugen-present-jefferies-2015-global-120000514.html
*********************************************************

$CGEN charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CGEN company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CGEN/company-info
Ticker: $CGEN
OTC Market Place: Not Available
CIK code: 0001119774
Company name: Compugen Ltd.
Company website: http://www.cgen.com
Incorporated In:

$CGEN share structure

## source: otcmarkets.com

Market Value: $378,918,870 a/o Nov 27, 2015
Shares Outstanding: 50,254,492 a/o Dec 31, 2014
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$CGEN extra dd links

Company name: Compugen Ltd.
Company website: http://www.cgen.com

## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CGEN+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CGEN+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CGEN+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/news - http://finance.yahoo.com/q/h?s=CGEN+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CGEN/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CGEN+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CGEN
DTCC (dtcc.com): http://search2.dtcc.com/?q=Compugen+Ltd.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Compugen+Ltd.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Compugen+Ltd.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://www.cgen.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://www.cgen.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://www.cgen.com

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CGEN
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001119774&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CGEN&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CGEN
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CGEN+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CGEN+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CGEN
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CGEN
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CGEN+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CGEN/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CGEN+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CGEN.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CGEN
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CGEN/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CGEN/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CGEN
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CGEN
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CGEN:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CGEN
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CGEN



$CGEN DD Notes ~ http://www.ddnotesmaker.com/CGEN

[corebts]

I'm in at $7. Long term hold. I think this company has great potential.

[d_shady]

Oh great the market is way down today too! I have a feeling this thing could open higher and drop. My opinion

[midastouch017]

Explains the huge pps drop!

[midastouch017]

Compugen Ltd. Prices Public Offering of Ordinary Shares

Friday 28 February 2014

Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) today announced that it has priced an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $10.50 per share. Gross proceeds to Compugen are expected to be $63 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Compugen. The offering is expected to close on or about March 5, 2014, subject to satisfaction of customary closing conditions. Compugen has granted the underwriters a thirty (30) day option to purchase up to 900,000 additional ordinary shares.

[surf1944]

9:27AM Compugen announced that it is significantly increasing its Pipeline Program activities in the field of immuno-oncology (CGEN) 9.53 :

Co announced that it is significantly increasing its Pipeline Program activities in the field of immuno-oncology. The primary purpose of the increase is to allow research and preclinical activities for a larger number of checkpoint target and product candidates for cancer immunotherapy to move forward in parallel. Additional objectives include the establishment of a biomarker discovery program for certain of the Company's checkpoint product candidates and the acceleration of experimental validation efforts for the recently disclosed antibody drug conjugate target candidates for oncology.
The significant increase in immuno-oncology activities during 2014 will impact both the target research and validation activities performed in Israel and the therapeutic antibody development efforts against Compugen-discovered drug targets undertaken by the Company's U.S. R&D subsidiary. This includes the scheduled relocation of the U.S. subsidiary to larger facilities in the South San Francisco area in mid-year.
"These expanded activities are anticipated to result in more than a sixty percent increase in our annual R&D cash expenditures, from approximately $10 mln in 2013 to more than $16 mln budgeted for 2014. Having begun 2014 with more than $50 mln in available resources, we are confident that this increased R&D budget, providing for a substantially expanded program in oncology while maintaining approximately the same level of expenditures for the immunology arm of our Pipeline Program, is fully consistent with our financial status and outlook."

[surf1944]

7:01AM Compugen discloses discovery of five potential cancer targets for antibody drug conjugate therapy (CGEN) 9.18 : Co announces the predictive discovery and selection of five candidate targets for antibody-drug conjugate cancer therapy. These five potential ADC targets, representing the initial results from the Company's second focused in silico discovery program, are now entering initial experimental validation to be followed by antibody discovery and development activities. Initial results are expected during the second half of 2014.

ADC target discovery is Compugen's second focused in silico discovery program, following the success of its first focused discovery program for the discovery of immune checkpoint targets for treatment of cancer and immune diseases.

[midastouch017]

Compugen Discloses Discovery of Five Potential Cancer Targets for Antibody Drug Conjugate Therapy

Wednesday 11 December 2013

ADC target discovery is Company’s second focused discovery program utilizing its in silico predictive discovery infrastructure

Compugen Ltd. (NASDAQ: CGEN) announced today the predictive discovery and selection of five candidate targets for antibody-drug conjugate (ADC) cancer therapy. These five potential ADC targets, representing the initial results from the Company’s second focused in silico discovery program, are now entering initial experimental validation to be followed by antibody discovery and development activities. Initial results are expected during the second half of 2014.

ADC therapy utilizes antibodies to selectively target proteins on the surface of cancer cells for the delivery of highly toxic chemicals. This selective delivery is designed to limit the damage to healthy tissues, thereby reducing the side effects as compared to chemotherapy. To date, two approved ADC drugs have demonstrated impressive clinical proof of concept for this exciting new class of oncology drugs, and there are multiple additional ADC drugs in clinical development. Therefore, the discovery of target proteins meeting the requirements for utilizing ADC technology in the treatment of cancer is an area of high industry interest.

ADC target discovery is Compugen's second focused in silico discovery program, following the success of its first focused discovery program for the discovery of immune checkpoint targets for treatment of cancer and immune diseases. Compugen’s ADC target discovery program, which was initiated earlier this year, utilizes the same underlying predictive discovery infrastructure as the Company’s earlier immune checkpoint program, with the addition of certain algorithms and other computational capabilities specifically developed for this effort. In both programs, the objective is to first identify an appropriate set of proteins with the support of the Company’s proprietary predictive human proteome, and then select from this set those proteins predicted to have the highest probability of meeting each program’s specific requirements.

More specifically for the ADC program, Compugen’s discovery infrastructure was expanded by incorporating additional algorithms that enable prediction of membrane proteins having the potential to internalize, that are both expressed on cancer cells and have low expression on healthy cells, in order to allow the ADC drug to selectively attack the tumor and spare healthy tissues. It was additionally enhanced to identify targets associated with advanced cancer stages and poor clinical outcome, in order to provide potential superior first-in-class treatment to patient populations with limited therapeutic options.

Dr. Anat Cohen-Dayag, Compugen’s President and CEO stated, “As we continue to invest most of our R&D and commercialization efforts on activities supporting our current Pipeline Program product candidates, which are largely based on our immune checkpoint discoveries, we are pleased to disclose these promising initial discoveries from our second focused discovery program.”

Dr. Cohen-Dayag continued, “Immune checkpoint regulators are generally considered to be the next frontier in the treatment of cancer; however, ADCs are recognized as an additional very promising class of highly potent and selective oncology drugs providing a different approach to cancer treatment. Therefore, in view of our successful track record of experimental validation for molecules selected by our unique predictive discovery infrastructure, we very much look forward to the potential for these ADC target candidates to further expand the scope and diversity of the cancer therapy arm of our pipeline.”

Dr. Cohen-Dayag added, “These discoveries demonstrate significant advantages that our predictive discovery methodology offers compared with traditional discovery. First, since the required discovery platform for this program was built through the enhancement of our existing infrastructure, the total time to date has been less than a year from initiation of the program. Furthermore, this enhanced capability will now be available for future discovery programs. Second, since this second program utilizes a different basis for selection and prioritization of results than the first program, it further demonstrates the applicability of our core predictive infrastructure to multiple areas of high industry interest. Third, as demonstrated by both programs, each focused discovery program has the potential to yield multiple possible novel product candidates.”

About ADC Cancer Therapy

ADC cancer therapy destroys cancer cells by delivering high-potency cytotoxic agents (the “payload”) directly to the cancer cells. The principle underlying ADC therapy is linking the toxic agent payload to an antibody or antibody fragment that specifically targets a protein present on the membrane of the cancer cell. After administration to the patient, the antibody with the payload specifically binds this membrane protein on the cancer cell and is then internalized into the cell where the payload is released and destroys it. Thus, unlike chemotherapies, ADC therapy is designed to specifically destroy only cells displaying this protein by targeting the appropriate protein on the cancer cell. ADCs against a number of targets, both in solid and hematologic tumors, are in clinical development, with two ADC products gaining FDA approval in the past two years.

[surf1944]

7:07AM Compugen presents experimental results supporting induction of immune tolerance by CGEN-15001 Drug Candidate; presentation will also disclose recent positive results from a humanized animal model of psoriasis (CGEN) 9.96 : Co disclosed results from an animal model study in which CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, demonstrated potential to induce immune tolerance, a much desired goal for treatment of many immunological disorders. The presentation will also disclose recent positive results from a humanized animal model of psoriasis, further expanding the scope of autoimmune conditions potentially treatable by CGEN-15001. In her presentation, Dr. Rotman will disclose results from a recently completed bone marrow transplantation study in which CGEN-15001 was highly effective in preventing graft rejection, suggesting that this drug candidate acts through an induction of immune tolerance. Establishment of immune tolerance is a key goal in the treatment of autoimmune diseases. In comparison to current therapeutic approaches that generally suppress the immune system, tolerance induction would provide a sustained resolution of the disease without compromising the immune system's capacity to fight infections and malignancies.

In this study, bone marrow cells from male mice were transplanted into female mice of the same strain, followed by monitoring of the number of male cells in their blood. In CGEN-15001 treated animals, successful engraftment of the transplanted bone marrow cells was observed, while in control animals the transplanted cells were rejected. These results suggest that treatment with CGEN-15001 induces immune tolerance towards the transplanted cells. Additional data will also be presented for CGEN-15001 supporting this highly desired mechanism of action in type 1 diabetes and multiple sclerosis animal models.

CGEN-15001 was injected into the skin graft starting on the day of disease induction, and the skin was subsequently analyzed for psoriatic histological characteristics. Results of this study demonstrated that treatment with CGEN-15001 was highly efficient in the prevention of psoriasis. Currently there is no cure for psoriasis, and treatment may include topical steroids, phototherapy, and systemic agents that suppress the immune system.

[surf1944]

7:06AM Compugen drug candidate demonstrates high effectiveness in Type I Diabetes animal model (CGEN) 9.42 : Co announces that CGEN-15001, an Fc fusion protein drug candidate derived from a novel immune checkpoint protein discovered by Compugen, has been shown to be highly efficient in preventing the development of disease in a well-accepted animal model of autoimmune type I diabetes, known also as juvenile diabetes.

Results of the study demonstrate that treatment with CGEN-15001 prevented development of diabetes throughout the 4 months of follow-up. Animals treated with CGEN-15001 maintained normal blood glucose levels compared with untreated animals that developed high blood glucose. The sustained duration of response following a short-term treatment with CGEN-15001, also observed previously in other disease models of autoimmunity, suggests that CGEN-15001 turns off the autoimmune process and may potentially lead to restoration of immune tolerance and resolution of autoimmunity, thereby arresting disease progression.

[CallmeBull]

Here comes the 10$ breaker!! Wow

[CallmeBull]

Wowow what a beast!!!!!

[midastouch017]

No doubt: Up!!!

[bcapps66]

The bigger question is, where does it go from here? The PPS that is.....

[midastouch017]

Compugen was worth the wait

Gali Weinreb

Compugen shows life sciences companies that invest heavily in science can achieve a breakthrough, even after the capital market has given up on them.

5 August 13 16:43, Gali Weinreb

Compugen Ltd. (Nasdaq: CGEN; TASE: CGEN), founded in the 1990s, was one of the prominent companies in the bio-informatics wave (combining computers and biology) that swept the world. It was believed at the time that cracking the genome and other advances in biology would move the drug discovery process from the laboratory to the computer. But the revolution stalled. Although computer systems improve the drug discovery process, most of the work is still done in the laboratory. Meanwhile, bio-informatics companies were stuck.
Compugen developed a system for automated data mining of biological information from a range of sources. When it was floated on Nasdaq in 2000, its business model was based on the sale of its data mining services to big pharma companies as user fees. Although it signed many cooperation agreements, revenue never exceeded a few million dollars a year.
In 2004, Compugen changed its business model to independently discover and develop drugs on the basis of its computing capabilities. It replaced all its management, board of directors, and a substantial part of its employees (mathematicians replaced biologists). But this did not help either, until the company found the right business model.
In 2010, Compugen decided to focus only on immune checkpoint drugs - molecules that induce the immune system to attack malignant tumors itself. One drug from this group, Yervoy, developed by Bristol Myers Squibb Co. (NYSE: BMY), was a great success, and other pharmaceutical companies rushed after other molecules from this group. Compugen's agreement today with Bayer Healthcare suggests that the bet paid off.
Compugen's story teaches that life sciences companies that invest heavily in time and effort in science over many years can achieve a breakthrough, even after the capital market has given up on them. This assumes that the outstanding science is accompanied by successful management (CEO Dr. Anat Cohen-Dayag) and a party that backs the company financially or can keep capital market enthusiasm alive (chairman Martin Gerstel).
But the lesson of the story is that it is not necessarily worthwhile to accompany a life sciences company all the way. Although Compugen's current market cap is double its IPO value, there were times when it was traded at a 90% discount on its IPO price.
Early investors in companies with such long roads rarely make a profit. When was it worthwhile to invest in Compugen? In 2010, when Cohen-Dayag announced that it was again changing direction, but by then, the market found it difficult to believe.
Published by Globes [online], Israel business news - www.globes-online.com - on August 5, 2013

[Al4343]

Could be just the "tip of the iceberg"...

Al

[surf1944]

6:26AM Compugen announces collaboration and license agreement with Bayer (BAYRY) for antibody-based cancer immunotherapies (CGEN) 5.46 : Co announced the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators. Under the terms of the agreement, Bayer HealthCare (BAYRY) and Compugen will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics. Under the agreement Compugen will receive an upfront payment of $10 million, and is eligible to receive over $500 million in potential milestone payments for both programs, not including milestone payments of up to $30 million associated with preclinical activities. Additionally, Compugen is also eligible to receive mid to high single digit royalties on global net sales of any resulting products under the collaboration.

[TheFinalCD]

Compugen Announces Collaboration and License Agreement with Bayer for Antibody-Based Cancer Immunotherapies



Compugen Ltd. - Ordinary Shares (MM) (NASDAQ:CGEN)
Intraday Stock Chart

Today : Monday 5 August 2013
Click Here for more Compugen Ltd. - Ordinary Shares (MM) Charts.

Compugen Ltd. (NASDAQ: CGEN) announced today the signing of a collaboration and license agreement for the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel Compugen discovered immune checkpoint regulators. Under the terms of the agreement, Bayer HealthCare (Bayer) and Compugen will jointly pursue a preclinical research program. Subsequently, Bayer will have full control over further development and have worldwide commercialization rights for potential cancer therapeutics.

Under the agreement Compugen will receive an upfront payment of USD 10 million, and is eligible to receive over USD 500 million in potential milestone payments for both programs, not including milestone payments of up to USD 30 million associated with preclinical activities. Additionally, Compugen is also eligible to receive mid to high single digit royalties on global net sales of any resulting products under the collaboration.

“Bayer is committed to translating the science of cancer research into effective therapies helping people affected by cancer live longer and improve their quality of life,” said Prof. Andreas Busch, Member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery. “Antibody-based immunotherapies are promising approaches in oncology which can stimulate the body’s own immune cells to fight cancer cells. Immunotherapy is one of our focus areas in oncology research. We are looking forward to expanding our portfolio in this area through partnering with Compugen.”

Anat Cohen-Dayag, Ph.D., President and CEO of Compugen, added, “We are very excited to initiate this collaboration with Bayer, a leading global life science company with a broadening oncology franchise, for the development of antibody-based cancer immunotherapies against these two promising novel immune checkpoint targets. In addition, we believe that the prediction and validation of these two targets, through the use of our broadly applicable predictive discovery infrastructure, provides additional validation for our long-term commitment to establishing this unique capability".

The immunotherapy approach aims at combatting cancer by stimulating the body's own immune cells. The tumor and its environment suppress the ability of cancer patients to develop an effective anti-tumor immune response and in this way protect both tumor growth and survival. Compugen has discovered two novel immune checkpoint regulators that potentially play a key role in immunosuppression. Researchers at Compugen are developing specific therapeutic antibodies that are geared to block the immunosuppressive function of these targets and to reactivate the patient's anti-tumor immune response in order to fight cancer.

About Cancer Immunotherapy

Latest cancer immunotherapies have demonstrated impressive clinical benefit, even for end-stage patients with difficult-to-treat tumors such as metastatic melanoma and non-small cell lung cancer. Unlike conventional cancer therapies, which act by directly targeting the cancer cells, resulting often in only transient clinical responses as cancer cells become resistant, clinical responses to cancer immunotherapy tend to be durable, sometimes resulting in dramatic long term survival and absence of resistance or recurrences.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.

On August 2, 2013 Compugen filed Form-6K with its financial statements for the six months ended June 30, 2013 and will host a public conference call at 10:00 AM ET on Wednesday, August 7, 2013 to discuss these results and any questions with respect to this press release. Further information regarding the conference call is provided in a separate press release issued today and on our website.

About Bayer HealthCare

The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which include statements related to the potential development and commercialization of antibody-based cancer immunotherapies against the Compugen-discovered immune checkpoint targets, potential milestone and royalty payments, and that the collaboration validates Compugen’s predictive discovery infrastructure, include words such as “may,” “expects,” “anticipates,” “potential,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks and other factors are discussed in the "Risk Factors" section of Compugen’s Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

[surf1944]

http://cgen.com/press-releases

[surf1944]

7:04AM Compugen discloses focused target discovery program for antibody-drug conjugate cancer therapy (CGEN) 5.26 : Co disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Co's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody drugs for cancer immunotherapy.

[surf1944]

7:56AM Compugen discloses focused target discovery program for antibody-drug conjugate cancer therapy (CGEN) : Co disclosed the initiation of its second focused discovery program, aimed at identification of novel targets for antibody-drug conjugate cancer therapy focusing on clinical situations with poor survival rates and/or recurrent cancers. This second program follows Compugen's successful initial focused discovery program for novel immune checkpoint proteins, a number of which have been incorporated in the Company's Pipeline Program as Fc fusion protein drugs for immunology and/or as therapeutic targets for monoclonal antibody drugs for cancer immunotherapy.

Second program follows initial program that resulted in discovery of multiple novel immune checkpoint molecules and establishment of Pipeline Program.
Initial discoveries from new program anticipated before year-end